List view / Grid view
A report has highlighted how the outsourcing of manufacturing activities to contract manufacturers is facilitating more streamlined and efficient pharmaceutical drug development.
In this exclusive interview, Dr Uwe Hanenberg, Head of Product Development at Recipharm discusses the current landscape and future innovations in oral solid dosage (OSD) formulation.
In this Q&A, Recipharm’s Torkel Gren discusses developments in capsule formulation, including the shift away from gelatine and the potential for growth in the inhalation capsule market.
This in-depth focus features articles on trends in capsule formulation and the evolving role of titanium dioxide in formulation.
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
Under the agreement, Recipharm will help advance two inhaled medicines intended for asthma and chronic obstructive pulmonary disease (COPD).
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm-300x278.jpg)
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm.jpg)
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
Market research suggests the Asia Pacific region could soon overtake Europe and North America in the active pharmaceutical ingredient (API) contract development and manufacturing organisation (CDMO) market.
Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
Here EPR summarises the latest news from Moderna on the licensure, supply and distribution of its mRNA COVID-19 vaccine.
Pharmaceutical manufacturing can lead to the contamination of water ways and supply. Here, the ultimate effects from pharma’s role in environmental pollution is examined.
Mark Quick, Executive Vice-president, Corporate Development at Recipharm, explains how his company has set about becoming a best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry.
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
